Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023
Anti-obesity Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Globally, obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.
Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.
Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.
Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors healthcare specialists have an undesirable insight and do not recommend them to their clients.
Market Analysis: The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2017–2023. The market is analyzed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India and China are set to be the most attractive destinations due to the large untapped market.
Types Analysis: The top FDA approved anti-obesity drugs are Xenical, Saxenda, Contrave, Belviq, and Qsymia. Xenical was the largest selling drug in the market until 2012, but saw a dip in its revenue over the years. However, recently approved Saxenda by Novo Nordisk is gaining large interest among obese people and is growing at a fast growth rate.
Key Players: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors.
Competitive Analysis: Novo Nordisk, an innovator of drugs in the obesity market, launched Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-oobesity drugs without further investing in the development of novel molecules.
Benefits: The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding business in this market.
Key Stakeholders:
Overview: Globally, obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.
Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.
Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.
Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors healthcare specialists have an undesirable insight and do not recommend them to their clients.
Market Analysis: The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2017–2023. The market is analyzed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India and China are set to be the most attractive destinations due to the large untapped market.
Types Analysis: The top FDA approved anti-obesity drugs are Xenical, Saxenda, Contrave, Belviq, and Qsymia. Xenical was the largest selling drug in the market until 2012, but saw a dip in its revenue over the years. However, recently approved Saxenda by Novo Nordisk is gaining large interest among obese people and is growing at a fast growth rate.
Key Players: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors.
Competitive Analysis: Novo Nordisk, an innovator of drugs in the obesity market, launched Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-oobesity drugs without further investing in the development of novel molecules.
Benefits: The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Total Addressable Market
3.3 Segmented Addressable Market
3.4 Related Markets
3.4.1 Diabetes Drugs
3.4.2 Active Pharmaceutical Ingredients
3.4.3 Intragastric Balloon
3.4.4 Oncology (Cancer) Drugs
4 MARKET OUTLOOK
4.1 Overview
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Evolution
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High prevalence of obesity
5.2.1.2 Unhealthy lifestyle
5.2.1.3 Chronic nature of obesity
5.2.2 Opportunities
5.2.2.1 Growing awareness of fitness
5.2.2.2 Large untapped market
5.2.3 Restraints
5.2.3.1 Side effects related to anti-obesity drugs
5.2.3.2 Availability of alternative treatment options
5.3 DRO – Impact Analysis
5.4 Key Stakeholders
6 DRUG DETAILS: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Orlistat
6.3 Phentermine/Topiramate ER
6.4 Lorcaserin
6.5 Naltrexone SR/Bupropion SR
6.6 Liraglutide 3.0 mg
7 TYPES: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prescription Drugs (Rx)
7.3 OTC Drugs
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 US
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Overview
8.3.2 UK
8.3.3 Germany
8.4 Asia Pacific
8.4.1 Overview
8.4.2 India
8.4.3 China
8.4.4 Australia
8.5 Rest of the World
8.5.1 Overview
8.5.2 Brazil
8.5.3 Africa
8.5.4 Middle East
9 COMPETITIVE LANDSCAPE
10 VENDORS PROFILES
10.1 F. Hoffmann-La Roche Ltd.
10.1.1 Overview
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 GlaxoSmithKline plc
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Vivus, Inc.
10.3.1 Overview
10.3.2 Business Focus
10.3.3 SWOT Analysis
10.3.4 Business Strategies
10.4 Orexigen Therapeutics, Inc.
10.4.1 Overview
10.4.2 Business Focus
10.4.3 SWOT Analysis
10.4.4 Business Strategies
10.5 Eisai Co., Ltd.
10.5.1 Overview
10.5.2 Geographic Revenue
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
11 COMPANIES TO WATCH FOR
11.1 Pfizer, Inc.
11.1.1 Overview
11.1.2 Highlights
11.2 Nova Nordisk A/S
11.2.1 Overview
11.2.2 Highlights
11.3 Boehringer Ingelheim GmbH
11.3.1 Overview
11.4 Rhythm Pharmaceuticals, Inc.
11.4.1 Overview
11.5 Zafgen, Inc.
11.5.1 Overview
11.6 Norgine B.V.
11.6.1 Overview
11.7 Merck & Co.
11.7.1 Overview
11.7.2 Highlights
11.8 Takeda Pharmaceutical Co., Ltd.
11.8.1 Overview
Annexure
Abbreviations
?
Tables
Table 1 ANTI-OBESITY DRUGS MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION)
Table 2 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 3 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 4 GLAXOSMITHKLINE PLC: OFFERINGS
Table 5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 6 VIVUS, INC.: OFFERINGS
Table 7 VIVUS, INC.: RECENT DEVELOPMENTS
Table 8 OREXIGEN THERAPEUTICS, INC.: OFFERINGS
Table 9 OREXIGEN THERAPEUTICS, INC.: RECENT DEVELOPMENTS
Table 10 EISAI CO., LTD.: OFFERINGS
Table 11 EISAI CO., LTD.: RECENT DEVELOPMENTS
Table 12 PFIZER: RECENT DEVELOPMENTS
Table 13 NOVO NORDISK: OVERVIEW
Table 14 NOVO NORDISK: RECENT DEVELOPMENTS
Table 15 BOEHRINGER INGELHEIM GMBH: OVERVIEW
Table 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
Table 17 RHYTHM PHARMACEUTICALS, INC.: OVERVIEW
Table 18 RHYTHM PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
Table 19 ZAFGEN: OVERVIEW
Table 20 NORGINE B.V.: OVERVIEW
Table 21 MERCK & CO.: OVERVIEW
Table 22 MERCK & CO.: RECENT DEVELOPMENTS
Table 23 TAKEDA PHARMACEUTICAL CO., LTD.: OVERVIEW
Table 24 TAKEDA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS
?
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL ANTI-OBESITY DRUGS MARKET
Chart 2 GLOBAL ANTI-OBESITY DRUGS MARKET REVENUE, 2016–2023 ($MILLION)
Chart 3 OBESITY-RELATED COST BY COUNTRY AS A PERCENTAGE OF TOTAL HEALTHCARE SPENDING (%)
Chart 4 SEGMENTATION OF GLOBAL ANTI-OBESITY DRUGS MARKET
Chart 5 PORTER 5 FORCES OF ANTI-OBESITY DRUGS MARKET
Chart 6 PEST ANALYSIS OF ANTI-OBESITY DRUGS MARKET
Chart 7 MARKET EVOLUTION
Chart 8 MARKET DYNAMICS – DRO ANALYSIS
Chart 9 DRO – IMPACT ANALYSIS OF GLOBAL ANTI-OBESITY DRUGS MARKET
Chart 10 KEY STAKEHOLDERS
Chart 11 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 ($MILLION)
Chart 12 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 ($MILLION)
Chart 13 PRESCRIPTION DRUGS (RX) MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 ($MILLION)
Chart 14 OTC DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 ($MILLION)
Chart 15 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2016 (%)
Chart 16 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2023 (%)
Chart 17 ANTI-OBESITY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2023 ($MILLION)
Chart 18 EUROPEAN COUNTRIES’ OBESITY RATE IN 2014
Chart 19 ANTI-OBESITY DRUGS MARKET REVENUE IN EUROPE, 2016–2023 ($MILLION)
Chart 20 ANTI-OBESITY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2016–2023 ($MILLION)
Chart 21 ANTI-OBESITY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 22 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 23 F. HOFFMANN-LA ROCHE: BUSINESS UNITS
Chart 24 F. HOFFMANN-LA ROCHE: GEOGRAPHIC REVENUE
Chart 25 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 26 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 27 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 28 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE
Chart 29 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 30 VIVUS, INC.: OVERVIEW SNAPSHOT
Chart 31 VIVUS, INC.: SWOT ANALYSIS
Chart 32 OREXIGEN THERAPEUTICS, INC.: OVERVIEW SNAPSHOT
Chart 33 OREXIGEN THERAPEUTICS, INC.: SWOT ANALYSIS
Chart 34 EISAI CO., LTD.: OVERVIEW SNAPSHOT
Chart 35 EISAI CO., LTD.: GEOGRAPHIC REVENUE
Chart 36 EISAI CO., LTD.: SWOT ANALYSIS
1.1 Industry Overview
1.2 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Total Addressable Market
3.3 Segmented Addressable Market
3.4 Related Markets
3.4.1 Diabetes Drugs
3.4.2 Active Pharmaceutical Ingredients
3.4.3 Intragastric Balloon
3.4.4 Oncology (Cancer) Drugs
4 MARKET OUTLOOK
4.1 Overview
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Evolution
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High prevalence of obesity
5.2.1.2 Unhealthy lifestyle
5.2.1.3 Chronic nature of obesity
5.2.2 Opportunities
5.2.2.1 Growing awareness of fitness
5.2.2.2 Large untapped market
5.2.3 Restraints
5.2.3.1 Side effects related to anti-obesity drugs
5.2.3.2 Availability of alternative treatment options
5.3 DRO – Impact Analysis
5.4 Key Stakeholders
6 DRUG DETAILS: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Orlistat
6.3 Phentermine/Topiramate ER
6.4 Lorcaserin
6.5 Naltrexone SR/Bupropion SR
6.6 Liraglutide 3.0 mg
7 TYPES: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prescription Drugs (Rx)
7.3 OTC Drugs
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 US
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Overview
8.3.2 UK
8.3.3 Germany
8.4 Asia Pacific
8.4.1 Overview
8.4.2 India
8.4.3 China
8.4.4 Australia
8.5 Rest of the World
8.5.1 Overview
8.5.2 Brazil
8.5.3 Africa
8.5.4 Middle East
9 COMPETITIVE LANDSCAPE
10 VENDORS PROFILES
10.1 F. Hoffmann-La Roche Ltd.
10.1.1 Overview
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 GlaxoSmithKline plc
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Vivus, Inc.
10.3.1 Overview
10.3.2 Business Focus
10.3.3 SWOT Analysis
10.3.4 Business Strategies
10.4 Orexigen Therapeutics, Inc.
10.4.1 Overview
10.4.2 Business Focus
10.4.3 SWOT Analysis
10.4.4 Business Strategies
10.5 Eisai Co., Ltd.
10.5.1 Overview
10.5.2 Geographic Revenue
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
11 COMPANIES TO WATCH FOR
11.1 Pfizer, Inc.
11.1.1 Overview
11.1.2 Highlights
11.2 Nova Nordisk A/S
11.2.1 Overview
11.2.2 Highlights
11.3 Boehringer Ingelheim GmbH
11.3.1 Overview
11.4 Rhythm Pharmaceuticals, Inc.
11.4.1 Overview
11.5 Zafgen, Inc.
11.5.1 Overview
11.6 Norgine B.V.
11.6.1 Overview
11.7 Merck & Co.
11.7.1 Overview
11.7.2 Highlights
11.8 Takeda Pharmaceutical Co., Ltd.
11.8.1 Overview
Annexure
Abbreviations
?
Tables
Table 1 ANTI-OBESITY DRUGS MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION)
Table 2 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 3 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 4 GLAXOSMITHKLINE PLC: OFFERINGS
Table 5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 6 VIVUS, INC.: OFFERINGS
Table 7 VIVUS, INC.: RECENT DEVELOPMENTS
Table 8 OREXIGEN THERAPEUTICS, INC.: OFFERINGS
Table 9 OREXIGEN THERAPEUTICS, INC.: RECENT DEVELOPMENTS
Table 10 EISAI CO., LTD.: OFFERINGS
Table 11 EISAI CO., LTD.: RECENT DEVELOPMENTS
Table 12 PFIZER: RECENT DEVELOPMENTS
Table 13 NOVO NORDISK: OVERVIEW
Table 14 NOVO NORDISK: RECENT DEVELOPMENTS
Table 15 BOEHRINGER INGELHEIM GMBH: OVERVIEW
Table 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
Table 17 RHYTHM PHARMACEUTICALS, INC.: OVERVIEW
Table 18 RHYTHM PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
Table 19 ZAFGEN: OVERVIEW
Table 20 NORGINE B.V.: OVERVIEW
Table 21 MERCK & CO.: OVERVIEW
Table 22 MERCK & CO.: RECENT DEVELOPMENTS
Table 23 TAKEDA PHARMACEUTICAL CO., LTD.: OVERVIEW
Table 24 TAKEDA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS
?
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL ANTI-OBESITY DRUGS MARKET
Chart 2 GLOBAL ANTI-OBESITY DRUGS MARKET REVENUE, 2016–2023 ($MILLION)
Chart 3 OBESITY-RELATED COST BY COUNTRY AS A PERCENTAGE OF TOTAL HEALTHCARE SPENDING (%)
Chart 4 SEGMENTATION OF GLOBAL ANTI-OBESITY DRUGS MARKET
Chart 5 PORTER 5 FORCES OF ANTI-OBESITY DRUGS MARKET
Chart 6 PEST ANALYSIS OF ANTI-OBESITY DRUGS MARKET
Chart 7 MARKET EVOLUTION
Chart 8 MARKET DYNAMICS – DRO ANALYSIS
Chart 9 DRO – IMPACT ANALYSIS OF GLOBAL ANTI-OBESITY DRUGS MARKET
Chart 10 KEY STAKEHOLDERS
Chart 11 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 ($MILLION)
Chart 12 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 ($MILLION)
Chart 13 PRESCRIPTION DRUGS (RX) MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 ($MILLION)
Chart 14 OTC DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 ($MILLION)
Chart 15 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2016 (%)
Chart 16 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2023 (%)
Chart 17 ANTI-OBESITY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2023 ($MILLION)
Chart 18 EUROPEAN COUNTRIES’ OBESITY RATE IN 2014
Chart 19 ANTI-OBESITY DRUGS MARKET REVENUE IN EUROPE, 2016–2023 ($MILLION)
Chart 20 ANTI-OBESITY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2016–2023 ($MILLION)
Chart 21 ANTI-OBESITY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 22 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 23 F. HOFFMANN-LA ROCHE: BUSINESS UNITS
Chart 24 F. HOFFMANN-LA ROCHE: GEOGRAPHIC REVENUE
Chart 25 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 26 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 27 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 28 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE
Chart 29 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 30 VIVUS, INC.: OVERVIEW SNAPSHOT
Chart 31 VIVUS, INC.: SWOT ANALYSIS
Chart 32 OREXIGEN THERAPEUTICS, INC.: OVERVIEW SNAPSHOT
Chart 33 OREXIGEN THERAPEUTICS, INC.: SWOT ANALYSIS
Chart 34 EISAI CO., LTD.: OVERVIEW SNAPSHOT
Chart 35 EISAI CO., LTD.: GEOGRAPHIC REVENUE
Chart 36 EISAI CO., LTD.: SWOT ANALYSIS
